Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Short term Debt (2020 - 2025)

Historic Short term Debt for P3 Health Partners (PIII) over the last 4 years, with Q3 2025 value amounting to $38.6 million.

  • P3 Health Partners' Short term Debt rose 1846346.15% to $38.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.6 million, marking a year-over-year increase of 1846346.15%. This contributed to the annual value of $75.2 million for FY2024, which is N/A changed from last year.
  • P3 Health Partners' Short term Debt amounted to $38.6 million in Q3 2025, which was up 1846346.15% from $80.0 million recorded in Q2 2025.
  • In the past 5 years, P3 Health Partners' Short term Debt registered a high of $80.0 million during Q2 2025, and its lowest value of $208000.0 during Q3 2024.
  • Its 3-year average for Short term Debt is $29.4 million, with a median of $2.4 million in 2022.
  • Data for P3 Health Partners' Short term Debt shows a peak YoY increase of 1846346.15% (in 2025) and a maximum YoY decrease of 441075.64% (in 2025) over the last 5 years.
  • Over the past 3 years, P3 Health Partners' Short term Debt (Quarter) stood at $1.2 million in 2022, then surged by 6278.64% to $75.2 million in 2024, then crashed by 48.62% to $38.6 million in 2025.
  • Its Short term Debt stands at $38.6 million for Q3 2025, versus $80.0 million for Q2 2025 and $65.0 million for Q1 2025.